Investigation of Recurrent Melioidosis in Lao People's Democratic Republic by Multilocus Sequence Typing. by Rachlin, Audrey et al.
LSHTM Research Online
Rachlin, Audrey; Dittrich, Sabine; Phommasone, Koukeo; Douangnouvong, Anousone; Phetsou-
vanh, Rattanaphone; Newton, Paul N; Dance, David AB; (2016) Investigation of Recurrent Me-
lioidosis in Lao People’s Democratic Republic by Multilocus Sequence Typing. AMERICAN JOUR-
NAL OF TROPICAL MEDICINE AND HYGIENE, 94 (6). pp. 1208-1211. ISSN 0002-9637 DOI:
https://doi.org/10.4269/ajtmh.15-0909
Downloaded from: http://researchonline.lshtm.ac.uk/4652777/
DOI: https://doi.org/10.4269/ajtmh.15-0909
Usage Guidlines:
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
Am. J. Trop. Med. Hyg., 94(6), 2016, pp. 1208–1211
doi:10.4269/ajtmh.15-0909
Copyright © 2016 by The American Society of Tropical Medicine and Hygiene
Investigation of Recurrent Melioidosis in Lao People’s Democratic Republic
by Multilocus Sequence Typing
Audrey Rachlin, Sabine Dittrich,* Koukeo Phommasone, Anousone Douangnouvong, Rattanaphone Phetsouvanh,
Paul N. Newton, and David A. B. Dance
London School of Hygiene and Tropical Medicine, London, United Kingdom; Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit,
Microbiology Laboratory, Mahosot Hospital, Vientiane, Lao People’s Democratic Republic; Centre for Tropical Medicine and Global Health,
University of Oxford, Oxford, United Kingdom
Abstract. Melioidosis is an infectious disease caused by the saprophytic bacterium Burkholderia pseudomallei.
In northeast Thailand and northern Australia, where the disease is highly endemic, a range of molecular tools have
been used to study its epidemiology and pathogenesis. In the Lao People’s Democratic Republic (Laos) where
melioidosis has been recognized as endemic since 1999, no such studies have been undertaken. We used a multilocus
sequence typing scheme specific for B. pseudomallei to investigate nine cases of culture-positive recurrence occurring in
514 patients with melioidosis between 2010 and 2015: four were suspected to be relapses while the other five represented
reinfections. In addition, two novel sequence types of the bacterium were identified. The low overall recurrence rates
(2.4%) and proportions of relapse and reinfection in the Laos are consistent with those described in the recent literature,
reflecting the effective use of appropriate antimicrobial therapy.
The gram-negative bacterium Burkholderia pseudomallei is
the cause of melioidosis, an infectious disease endemic through-
out the tropics, especially southeast Asia and northern Australia.
Case fatality rates range between 14% and 40%, even with
appropriate treatment, and recurrence is a potential problem in
those who survive.1,2 In the past, recurrence was found to occur
in as many as 13–23% of melioidosis patients, with genotyping
of initial and recurrent isolates suggesting that most of these
were relapses due to failure to eradicate the initial infecting
strain.2–4 The use of longer courses of treatment in countries
such as Thailand and Australia has dramatically reduced the
overall recurrence rate to as low as 1.2–7%.1,4 Furthermore,
the proportion of recurrences attributed to reinfection as
opposed to relapse has increased.1,4,5
Melioidosis was first described in the Lao People’s Demo-
cratic Republic (Laos) in 1999 but is now known to be highly
endemic, with more than 920 culture-positive cases diag-
nosed by the Microbiology Laboratory of Mahosot Hospital,
Vientiane, in the past 15 years (unpublished data). Despite
problems of affordability,6 international consensus guidelines
for treatment are usually followed, comprising ceftazidime for
at least 10–14 days followed by co-trimoxazole for 12–20 weeks
(combined with doxycycline, before the publication of the
MERTH study in 2014).1,6,7
Multilocus sequence typing (MLST) has emerged as an
effective tool to differentiate between relapses and reinfections
in melioidosis.3,8 We have reviewed the incidence of recurrence
in Lao patients and used MLST to investigate whether these
cases were attributable to relapse or reinfection.
All patients from whom B. pseudomallei was isolated between
1999 and 2015 in the Microbiology Laboratory of Mahosot
Hospital were recorded in a database. Bacteria were isolated
during studies of the etiology of fever in Laos, and isolates
were stored at −80°C. Ethical approval for the study was
obtained from the Oxford Tropical Research Ethics Com-
mittee and The National Ethics Committee for Health Research,
Laos. Culture-confirmed cases occurring after January 1, 2010,
were included in the analysis. Recurrence was defined as
the development of symptoms compatible with melioidosis
after completion of treatment, associated with the isolation of
B. pseudomallei from any clinical sample.
Genomic DNA was isolated using the Qiagen Mini Kit
(Hilden, Germany) according to the manufacturer’s instruc-
tions. Seven housekeeping alleles were amplified by polymer-
ase chain reaction (PCR) for each isolate using the described
MLST scheme.9 PCR products were analyzed on a 1.5% aga-
rose gel (Seakem LE Agarose, Lonza, Visp, Switzerland) and,
depending on purity, target amplicons were either processed
by ethanol purification or gel extraction (QIAquick; Qiagen) and
sequenced (Macrogen, Korea) on both forward and reverse
strands. Only high-quality consensus sequences were subse-
quently used for final analysis using CLC Genomics Workbench
7.0 software (Qiagen). Consensuses were edited to the appropri-
ate allele length before being entered into the MLST online
database (available at: http://pubmlst.org/bpseudomallei/) for
allele number assignment. Allele numbers were compiled into a
series of seven integers corresponding to the gene order of
ace-gltB-gmhD-lepA-lipA-narK-ndh, giving an allele profile
for each isolate. The allele profiles were queried against the
B. pseudomallei MLST website to obtain a sequence type (ST).
The Fisher’s exact test was used to assess categorical variables
using Stata software (College Station, TX), and a P value
< 0.05 was considered statistically significant.
Overall, 370 of 514 (72%) patients admitted after January 1,
2010, survived to be discharged from the hospital, and among
these, nine (9/370, 2.4%) had culture-positive recurrence. Ini-
tial and recurrent isolates from all nine patients were available
for analysis, and details of the patients and isolates are
given in Table 1. The nine patients were between 2 and 63
(median: 42.4) years of age at the time of initial hospitali-
zation, and the majority (6/9, 66.7%) were from Vientiane
Capital or the adjacent Vientiane Province. Nearly all patients
(7/9, 77.8%) had an underlying medical condition or occu-
pation that would put them at a greater risk for infection,
most notably farming (3/9, 33.3%) and diabetes mellitus (6/9,
66.7%), or both (3/9, 33.3%). Recurrent melioidosis was fatal
*Address correspondence to Sabine Dittrich, Lao-Oxford-Mahosot
Hospital-Wellcome Trust Research Unit, Microbiology Laboratory,
Mahosot Hospital, Vientiane, Lao People’s Democratic Republic.
E-mail: sabine-dittrich@gmx.de
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1209RECURRENT MELIOIDOSIS IN LAOS
in only one of the nine patients (MM384). In four cases
(including two of the patients classified as relapses) ceftazidime
was given for longer than 10–14 days often recommended
during their initial illness, reflecting slow fever clearance and
multifocal disease.
MLST profiles were assigned to all primary and secondary
isolates (Table 2). On the basis of the MLST results, four of
the nine patients, representing 0.78% (4/514) of all culture-
confirmed melioidosis cases, were identified as probable relapses,
as the STs of the primary and recurrent isolates were identical.
The time to recurrence was between 2 and 32 (median: 13.5)
months (Table 1). One of these (MM476) presented with symp-
toms and signs of recurrence while still on treatment with oral
co-amoxiclav, although his adherence was uncertain, and is
thus best considered as a case of recrudescence. Five patients
(5/9, 55.5%) had initial and recurrent isolates with different
STs, suggesting reinfection. The time to recurrence for these
five patients was between 13 and 47 (median: 24.6) months.
The median times to relapse and to reinfection were not signifi-
cantly different (P = 0.17), but the number of cases analyzed
was small. Two of the isolates, MM360.2 and MM452.2, had
novel allele profiles and were subsequently assigned as ST1428
and ST1429, by the MLST database curator, respectively.
The results of this study provide evidence for a low recur-
rence rate (2.4%) of melioidosis in Laos, consistent with recent
literature from other countries.5 Our data also suggest that,
as elsewhere, recurrent melioidosis in this small number of
cases from Laos was more frequently due to reinfection than
relapse.3–5 This reflects the fact that considerable efforts have
been made to implement international consensus antimicro-
bial therapy for melioidosis in Laos.
Although it is possible that some patients with recurrent
infections might have been missed, for example, if they had
died at home or presented to other hospitals where melioidosis
could not be diagnosed by culture, great attention was paid
ensuring compliance with treatment and with follow-up. The
risk of relapse and importance of completing a full course of
eradication treatment was repeatedly stressed to the patients
and their family whenever possible, or their physicians when
they were in hospitals other than Mahosot Hospital. On the
completion of intensive phase treatment, patients were given
a card describing the treatment plan and were asked to return
regularly for follow-up at Mahosot Hospital, although this
was not possible for the three patients (MM439, MM452, and
MM562) under treatment in other hospitals. During follow-up
visits, patients were asked about adherence, although this
was not formally assessed, for example, by testing urinary
antimicrobial activity. Antibiotics were provided free of charge
to individuals not able to afford them. Consequently, we do
not believe that access to medicines is likely to have been a
significant problem.
Burkholderia pseudomallei has been shown to possess a
high degree of strain diversity in both Thailand and northern
Australia.10–12 Consistent with these findings, 13 different STs
were identified among the 18 isolates from Laos, including
two novel STs. The high degree of diversity makes it likely
that that the four cases of recurrence we identified with the
same ST are genuine relapses, although reinfection by the
same strain cannot be completely ruled out.
Similarly, we assumed that individual infections were not
caused by multiple B. pseudomallei strains, although polyclonal
infections have occasionally been identified in melioidosis
patients.13,14 If only a single ST were isolated and saved during
a primary mixed infection, relapse could still have occurred
with a different ST that had been present initially. In addi-
tion, if a polyclonal infection were to have occurred in one
of these patients, it could have resulted in recombination
between bacterial strains. Though unlikely, this may have led
to modifications within an allele fragment, enough to warrant
it being assigned a new allele number.14,15 Finally, microevolu-
tion occurring during the course of infection might occasion-
ally result in a change of ST.15 All of these mechanisms could
have resulted in relapses being wrongly classified as reinfec-
tions. However, since polyclonal infection does not appear
to be common, and since none of our recurrent isolates were
single locus variants of the initial strain, we consider this to be
relatively unlikely.16
Collectively, our data suggest that appropriate antimicrobial
therapy is being used in Laos for the treatment of melioidosis
and that effective treatment of B. pseudomallei is possible in
resource-limited settings if evidence-based treatment regimens
are used. Studies utilizing higher resolution molecular indexing
tools, such as whole-genome sequencing, will help to clarify
whether this breakdown into relapse and reinfection is correct
and assist with further epidemiological studies of melioidosis
in Laos.
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TABLE 2
Allele profiles and STs for the 18 isolates as assigned by the online
Burkholderia pseudomallei multilocus sequence typing database
(http://bpseudomallei.mlst.net/)
Sample ID ace gltB gmhD lepA lipA narK ndh ST
MM321 3 1 2 2 1 11 1 ST52
MM321.2 3 1 2 2 1 11 1 ST52
MM360 3 1 4 1 1 4 1 ST56
MM360.2 1 4 13 2 1 11 1 ST1428*
MM363 1 1 2 1 6 4 1 ST1004
MM363.2 1 1 3 3 1 2 1 ST488
MM384 3 1 4 3 1 4 3 ST375
MM384.2 3 1 4 3 1 4 3 ST375
MM439 1 4 2 3 8 4 3 ST376
MM439.2 1 4 2 1 1 4 3 ST658
MM452 1 1 13 1 1 1 1 ST10
MM452.2 1 4 13 1 1 1 3 ST1429*
MM476 3 1 4 1 1 4 1 ST56
MM476.2 3 1 4 1 1 4 1 ST56
MM545 1 2 3 1 1 3 1 ST307
MM545.2 3 1 11 3 5 4 6 ST507
MM562 3 4 11 3 5 4 6 ST70
MM562.2 3 4 11 3 5 4 6 ST70
STs = sequence types. Recurrent infections have been designated with “.2” in sample IDs.
*ST first described in this publication.
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